Skip to content
Amanta Healthcare logo

Amanta Healthcare

AMANTA NSE
₹184.91 +12.43 (+7.21%)
P/E
49.05
View as Markdown
MCP
Close 4 Nov 2026 ₹184.91 +64.81 +54.0% 1Y
Start ₹120.10

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
11.60%
Debt to Equity
1.11
EPS (TTM)
₹3.77
Book Value
₹56.71
Market Cap
—
P/E (TTM)
49.05
P/B
3.26
ROE
10.30%
Dividend Yield
0.00%
EBITDA
₹63.20 Cr
52W High
₹209.95
52W Low
₹92.00
Day Range
₹174.00 – ₹198.95
Volume
5,63,126

Peer Comparison

Healthcare › Pharmaceuticals

Amanta Healthcare peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Amanta Healthcare (this company)
₹184.9149.05₹749 Cr3.260.00%10.30%11.60%₹291 Cr₹15 Cr
Median 8 companies₹1,587.7043.93₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

35 Poor

Data confidence 100/100

Category scores

Quality
47
Average
Returns, margins, earnings quality 22% weight
Valuation
38
Weak
Cheap vs sector & own history 24% weight
Growth
27
Poor
Sales & profit trajectory 9% weight
Financial Health
18
Poor
Solvency, leverage, coverage 9% weight
Momentum
70
Strong
Trend strength, vol-adjusted 12% weight
Ownership
18
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 22.4% CAGR over last 5 years

Weaknesses

4
  • Stock is trading at 3.23 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 10.9% over past five years.
  • Company has a low return on equity of 10.0% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2611
OscillatorsBullish162
Moving AveragesStrong Bullish109

Key readings

RSI (14)
55.53
Neutral
MACD (12,26,9)
−4.28
Bullish
SMA (50)
185.32
Bearish
SMA (200)
145.08
Bullish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+10.99%
3Y+3.60%
1Y+4.73%
TTM+7.08%

Net profit

Net profit growth by window
5YTurned to profit
3YTurned to profit
1Y+50.00%
TTM−8.31%

Operating cash flow

Operating cash flow growth by window
5Y+9.14%
3Y+3.73%
1Y+2.13%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−1.39 pp
3Y+0.37 pp
1Y−0.99 pp
TTM−2.66 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹184 Cr
Mar 2021₹171 Cr
Mar 2022₹225 Cr
Mar 2023₹259 Cr
Mar 2024₹280 Cr
Mar 2025₹275 Cr
Mar 2026₹288 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020−₹19.00 Cr
Mar 2021−₹22.00 Cr
Mar 2022₹55.00 Cr
Mar 2023−₹2.00 Cr
Mar 2024₹4.00 Cr
Mar 2025₹10.00 Cr
Mar 2026₹15.00 Cr

Quarterly Results

₹ Cr
AMANTA quarterly results, ₹ crore
Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
68.1
66.73
67.81
72.06
65.31
70.89
74.49
76.99
68.8
83.13
Expenses
54.7
52.85
52.75
53.1
50.41
56.24
59.13
62.03
54.26
65.94
Operating Profit
13.4
13.88
15.06
18.96
14.9
14.65
15.36
14.96
14.54
17.19
OPM %
19.68%
20.8%
22.21%
26.31%
22.81%
20.67%
20.62%
19.43%
21.13%
20.68%
Other Income
0.15
0.21
0.87
0.16
0.96
−2.56
0.68
1.66
0.64
0.76
Interest
9.45
6.32
5.9
6.28
6.29
5.15
5.06
4.25
6
5.84
Depreciation
4.6
4.6
4.51
4.69
4.64
4.66
4.67
4.75
4.69
5.28
PBT
−0.5
3.17
5.52
8.15
4.93
2.28
6.31
7.62
4.49
6.83
Tax %
−28%
28.71%
22.64%
26.87%
28.8%
46.93%
26.47%
27.43%
26.28%
28.84%
Net Profit
−0.36
2.26
4.28
5.96
3.51
1.21
4.63
5.53
3.31
4.86
EPS (₹)
−0.13
0.78
1.48
2.07
1.22
0.31
1.19
1.42
0.85
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
AMANTA profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
184
171
225
259
280
275
288
291
Expenses
147
133
173
206
223
215
228
232
Operating Profit
37
38
52
53
58
60
60
60
OPM %
20%
22%
23%
20%
21%
22%
21%
20%
Other Income
2
1
76
4
1
1
1
0
Interest
38
40
49
35
34
28
21
20
Depreciation
16
17
17
18
20
18
19
19
PBT
−15
−18
62
3
5
15
21
21
Tax %
25%
23%
11%
179%
32%
29%
30%
—
Net Profit
−19
−22
55
−2
4
10
15
15
EPS (₹)
−7.03
−8.14
20.54
−0.79
1.35
3.64
3.83
3.77
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
AMANTA balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
27
27
27
27
27
29
39
Reserves
2
−20
36
36
39
68
181
Borrowings
231
235
226
216
211
204
244
Other Liabilities
127
150
104
96
75
81
93
Total Liabilities
388
392
392
374
352
382
558
Fixed Assets
244
242
240
232
228
217
207
CWIP
0
0
0
9
0
7
82
Investments
0
2
3
0
4
8
7
Other Assets
144
149
149
133
120
150
262
Total Assets
388
392
392
374
352
382
558

Cash Flow

₹ Cr
AMANTA cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
38
31
62
43
58
47
48
Investing
−9
−13
−6
−7
−10
−24
−94
Financing
−37
−18
−50
−42
−46
−23
126
Net Cash Flow
−8
0
6
−6
1
−1
81
Free Cash Flow
27
19
52
36
46
26
−32
CFO/EBITDA
102
66
119
93
111
84
93

Ratios

AMANTA financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
104
110
73
75
63
67
55
Inventory Days
225
422
338
247
309
464
530
Days Payable
99
186
185
130
129
194
230
Cash Conversion Cycle
229
345
226
193
243
336
354
Working Capital Days
51
−5
28
42
16
26
6
ROCE %
—
9%
14%
13%
14%
15%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Amanta Healthcare insights

61 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.80%
  • Public 18.31%
  • DIIs 12.20%
  • Others 5.62%
  • FIIs 0.07%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Amanta Healthcare

What does Amanta Healthcare Ltd do?
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products.
Where is Amanta Healthcare Ltd (AMANTA) listed?
Amanta Healthcare Ltd trades as AMANTA on the NSE and under code 544502 on the BSE.
Which sector does Amanta Healthcare Ltd belong to?
Amanta Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Amanta Healthcare Ltd?
Amanta Healthcare Ltd trades at a PE ratio of 49.05 as of 4 Nov 2026, on earnings per share of ₹3.77, against a book value of ₹56.71 per share.
What is the 52-week high and low of Amanta Healthcare Ltd?
Over the last 52 weeks Amanta Healthcare Ltd has traded between ₹92 and ₹209.95 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Amanta Healthcare Ltd?
Amanta Healthcare Ltd reported a return on equity of 10.30%. Its debt-to-equity ratio is 1.11.

Company Information

Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products.

Website amanta.co.in
CEO Mr. Bhavesh Girishbhai Patel
Listed 9 Sep 2025
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AMANTA.md for Amanta Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month